Wells Fargo & Company MN Trims Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Wells Fargo & Company MN cut its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 2.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 150,519 shares of the company’s stock after selling 3,093 shares during the quarter. Wells Fargo & Company MN owned about 0.17% of IDEAYA Biosciences worth $3,868,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IDYA. Rhumbline Advisers increased its position in shares of IDEAYA Biosciences by 0.5% during the fourth quarter. Rhumbline Advisers now owns 113,561 shares of the company’s stock valued at $2,919,000 after acquiring an additional 585 shares during the last quarter. Daiwa Securities Group Inc. raised its position in IDEAYA Biosciences by 44.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock valued at $72,000 after purchasing an additional 853 shares during the period. Assetmark Inc. lifted its stake in IDEAYA Biosciences by 2.5% during the fourth quarter. Assetmark Inc. now owns 45,269 shares of the company’s stock worth $1,163,000 after purchasing an additional 1,084 shares in the last quarter. R Squared Ltd purchased a new position in shares of IDEAYA Biosciences during the fourth quarter worth $35,000. Finally, NEOS Investment Management LLC grew its stake in shares of IDEAYA Biosciences by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 16,066 shares of the company’s stock valued at $413,000 after buying an additional 1,577 shares in the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

IDYA has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Stephens restated an “overweight” rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a report on Friday, February 14th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Two equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $53.58.

IDEAYA Biosciences Trading Up 6.4 %

IDYA stock opened at $18.18 on Tuesday. The company’s 50 day moving average is $18.16 and its two-hundred day moving average is $23.68. IDEAYA Biosciences, Inc. has a twelve month low of $13.45 and a twelve month high of $44.42. The stock has a market cap of $1.59 billion, a P/E ratio of -5.51 and a beta of 0.51.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The business had revenue of $7.00 million for the quarter, compared to the consensus estimate of $7.00 million. On average, equities research analysts predict that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.